At JY BioMed, we are advancing an antibody-drug conjugate (ADC) platform targeting CEACAM6, a cell surface glycoprotein highly expressed in several solid tumors. Our investigational ADC combines a humanized heavy chain antibody (HCAb) specific for CEACAM6 with a cytotoxic payload, aiming to achieve selective tumor cell killing while minimizing systemic toxicity. 

The use of a smaller heavy chain antibody structure is designed to enhance tumor penetration and drug delivery efficiency.

Current research focuses on indications such as colorectal and pancreatic cancers, where CEACAM6 overexpression is associated with disease progression and poor prognosis.

​

The Anti-CEACAM6 ADC program remains under preclinical discovery and validation, with development activities conducted in alignment with global standards for targeted biologic therapeutics.